• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2 型糖尿病患者的共病、血糖变异性和目标范围内时间:GP-OSMOTIC 试验的基线分析。

Multimorbidity, glycaemic variability and time in target range in people with type 2 diabetes: A baseline analysis of the GP-OSMOTIC trial.

机构信息

Department of General Practice, University of Melbourne, Australia.

Department of General Practice, University of Melbourne, Australia.

出版信息

Diabetes Res Clin Pract. 2020 Nov;169:108451. doi: 10.1016/j.diabres.2020.108451. Epub 2020 Sep 17.

DOI:10.1016/j.diabres.2020.108451
PMID:32949650
Abstract

AIMS

To explore associations between multimorbidity condition counts (total; concordant (diabetes-related); discordant (unrelated to diabetes)) and glycaemia (HbA1c; glycaemic variability (GV); time in range (TIR)) using data from a randomised controlled trial examining effectiveness of continuous glucose monitoring (CGM) in people with type 2 diabetes (T2D).

METHODS

Cross-sectional study: 279 people with T2D using baseline data from the General Practice Optimising Structured MOnitoring To Improve Clinical outcomes (GP-OSMOTIC) trial from 25 general practices in Australia. Number of long-term conditions (LTCs) in addition to T2D used to quantify total/concordant/discordant multimorbidity counts. GV (measured by coefficient of variation (CV)) and TIR derived from CGM data. Multivariable linear regression models used to examine associations between multimorbidity counts, HbA1c (%), GV and TIR.

RESULTS

Mean (SD) age of participants 60.4 (9.9) years; 40.9% female. Multimorbidity was present in 89.2% of participants. Most prevalent comorbid LTCs: hypertension (57.4%), painful conditions (29.8%), coronary heart disease (22.6%) and depression (19.0%). No evidence of associations between multimorbidity counts, HbA1c, GV and TIR.

CONCLUSIONS

While multimorbidity was common in this T2D cohort, it was not associated with HbA1c, CV or TIR. Future studies should explore factors other than glycaemia that contribute to the increased mortality observed in those with multimorbidity and T2D.

摘要

目的

利用来自一项随机对照试验的数据分析多重合并症的条件计数(总数;一致的(与糖尿病相关);不一致的(与糖尿病无关))与血糖(HbA1c;血糖变异性(GV);达标时间(TIR))之间的关系,该试验旨在检查连续血糖监测(CGM)在 2 型糖尿病(T2D)患者中的有效性。

方法

横断面研究:来自澳大利亚 25 家普通实践的 General Practice Optimising Structured MOnitoring To Improve Clinical outcomes(GP-OSMOTIC)试验的 279 名 T2D 患者使用基线数据。除 T2D 之外,还使用长期合并症(LTCs)的数量来量化总/一致/不一致的多重合并症计数。CGM 数据得出的 GV(通过变异系数(CV)衡量)和 TIR。使用多变量线性回归模型来检验多重合并症计数、HbA1c(%)、GV 和 TIR 之间的关联。

结果

参与者的平均(SD)年龄为 60.4(9.9)岁;40.9%为女性。89.2%的参与者存在多重合并症。最常见的合并 LTCs:高血压(57.4%)、疼痛性疾病(29.8%)、冠心病(22.6%)和抑郁症(19.0%)。没有证据表明多重合并症计数、HbA1c、GV 和 TIR 之间存在关联。

结论

尽管在该 T2D 队列中普遍存在多重合并症,但它与 HbA1c、CV 或 TIR 无关。未来的研究应该探讨除血糖以外的其他因素,这些因素可能导致患有多重合并症和 T2D 的患者死亡率增加。

相似文献

1
Multimorbidity, glycaemic variability and time in target range in people with type 2 diabetes: A baseline analysis of the GP-OSMOTIC trial.2 型糖尿病患者的共病、血糖变异性和目标范围内时间:GP-OSMOTIC 试验的基线分析。
Diabetes Res Clin Pract. 2020 Nov;169:108451. doi: 10.1016/j.diabres.2020.108451. Epub 2020 Sep 17.
2
Associations between multimorbidity and glycaemia (HbA1c) in people with type 2 diabetes: cross-sectional study in Australian general practice.2型糖尿病患者中多种疾病与血糖(糖化血红蛋白)之间的关联:澳大利亚全科医疗的横断面研究
BMJ Open. 2020 Nov 26;10(11):e039625. doi: 10.1136/bmjopen-2020-039625.
3
Socioeconomic status and time in glucose target range in people with type 2 diabetes: a baseline analysis of the GP-OSMOTIC study.2型糖尿病患者的社会经济地位与血糖目标范围内的时间:GP-OSMOTIC研究的基线分析
BMC Endocr Disord. 2018 Jul 21;18(1):47. doi: 10.1186/s12902-018-0279-6.
4
Multimorbidity, mortality, and HbA1c in type 2 diabetes: A cohort study with UK and Taiwanese cohorts.2 型糖尿病的多种合并症、死亡率和糖化血红蛋白:一项英国和中国台湾队列研究。
PLoS Med. 2020 May 7;17(5):e1003094. doi: 10.1371/journal.pmed.1003094. eCollection 2020 May.
5
The continuous spectrum of glycaemic variability changes with pancreatic islet function: A multicentre cross-sectional study in China.血糖变异性的连续谱随胰岛功能变化:中国多中心横断面研究。
Diabetes Metab Res Rev. 2022 Nov;38(8):e3579. doi: 10.1002/dmrr.3579. Epub 2022 Oct 25.
6
Associations between multimorbidity, all-cause mortality and glycaemia in people with type 2 diabetes: A systematic review.2 型糖尿病患者的共病、全因死亡率与血糖之间的关联:系统综述。
PLoS One. 2018 Dec 26;13(12):e0209585. doi: 10.1371/journal.pone.0209585. eCollection 2018.
7
Multimorbidity and achievement of treatment goals among patients with type 2 diabetes: a primary care, real-world study.2 型糖尿病患者的多种合并症与治疗目标达标情况:一项初级保健、真实世界研究。
BMC Health Serv Res. 2021 Sep 14;21(1):964. doi: 10.1186/s12913-021-06989-x.
8
The impact of structured self-monitoring of blood glucose on glycaemic variability in non-insulin treated type 2 diabetes: The SMBG study, a 12-month randomised controlled trial.血糖自我结构化监测对非胰岛素治疗的2型糖尿病患者血糖变异性的影响:SMBG研究,一项为期12个月的随机对照试验。
Diabetes Metab Syndr. 2020 Mar-Apr;14(2):101-106. doi: 10.1016/j.dsx.2020.01.006. Epub 2020 Jan 13.
9
Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial.在一般实践中(GP-OSMOTIC),每 3 个月使用专业模式的即时血糖监测,对 2 型糖尿病成人进行监测:一项实用、开放标签、12 个月、随机对照试验。
Lancet Diabetes Endocrinol. 2020 Jan;8(1):17-26. doi: 10.1016/S2213-8587(19)30385-7.
10
Continuous glucose monitoring to assess glucose variability in type 3c diabetes.连续血糖监测评估 3c 型糖尿病的血糖变异性。
Diabet Med. 2022 Aug;39(8):e14882. doi: 10.1111/dme.14882. Epub 2022 May 23.

引用本文的文献

1
Multimorbidity, Frailty and Diabetes in Older People-Identifying Interrelationships and Outcomes.老年人的多重疾病、衰弱与糖尿病——识别相互关系及结果
J Pers Med. 2022 Nov 16;12(11):1911. doi: 10.3390/jpm12111911.
2
Multimorbidity and catastrophic health expenditure among patients with diabetes in China: a nationwide population-based study.中国糖尿病患者的多病共存和灾难性卫生支出:一项全国性基于人群的研究。
BMJ Glob Health. 2022 Feb;7(2). doi: 10.1136/bmjgh-2021-007714.